Furui: Lower target price of LAOPU GOLD (06181) to 981 Hong Kong dollars. High gold prices suppress gross profit.
Furui is expected to have a net profit of 2.3 billion yuan in the second half of 2025, a year-on-year increase of 155%, with sales of 15.3 billion yuan, a year-on-year increase of 207%.
Furui released a research report stating that it has lowered the target price of LAOPU GOLD (06181) from HK$1,103 to HK$981, corresponding to forecasted P/E ratios of 22 times and 17 times for 2026 and 2027, respectively. Despite facing pressure on profit margins, the bank expects LAOPU GOLD to see a recovery this year and has reiterated its "buy" rating.
Furui forecasts that LAOPU GOLD's net profit in the second half of 2025 will be 2.3 billion RMB, a year-on-year increase of 155%, with sales revenue of 15.3 billion RMB, a year-on-year increase of 207%. The bank has revised down its net profit forecasts for LAOPU GOLD in 2025 to 2027 by 14%, 6%, and 12%, respectively, to reflect the lower gross profit margin due to high gold prices and the return to normal growth in 2027.
Furui predicts that LAOPU GOLD will achieve a net profit of 2.3 billion RMB in the second half of 2025. In the mainland Chinese market, it predicts sales revenue of 13 billion RMB, a year-on-year increase of 188%, with the average sales per store increasing by 130% annually. In overseas markets, it forecasts sales revenue of 2.2 billion RMB, a year-on-year increase of 295%. During the period, the gross profit margin is expected to be 36.4%, compared to 38.1% in the first half of the year.
Related Articles

FDB Holdings (01826) will be suspended from trading starting from January 13th, awaiting the publication of insider information.

Research report by China Securities Co., Ltd.: Multi-model capabilities to build barriers MiniMax (00100) opens a new cycle of AI value realization.

ABBISKO-B(02256) Betjemai NDA accepted by FDA for the treatment of TGCT
FDB Holdings (01826) will be suspended from trading starting from January 13th, awaiting the publication of insider information.

Research report by China Securities Co., Ltd.: Multi-model capabilities to build barriers MiniMax (00100) opens a new cycle of AI value realization.

ABBISKO-B(02256) Betjemai NDA accepted by FDA for the treatment of TGCT

RECOMMEND

Institutions Bullish On Hong Kong Stocks As Spring Rally Builds; Domestic And Foreign Capital Increase ETF Allocations
13/01/2026

The Sword Over Hong Kong Stocks: IPO Peaks And Unlocking Waves
13/01/2026

Learning From History: The AI Investment Wave Likely To End This Year, But The Fed May Shield U.S. Stocks
13/01/2026


